News for Zai Lab Limited (ZLAB)

Zai Lab Ltd (NASDAQ:ZLAB) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On June 30, Leerink Partners raised its price target for the stock to $75 from $73. The research firm also reiterated an ‘Outperform’ rating on the stock. The research firm hiked its price target following positive Phase […]

Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2025. Novocure is a global oncology company working to exte

Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Friday. Shares of Netflix, Inc. NFLX fell in pre-market tradi...

PR NewswireVANCOUVER. BC, July 16, 2025 Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER. BC, July 16, 2025 /PRNewswire/

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its second quarter 2025 financial results and provide recent corporate updates o

Amgen & Zai Lab's trial shows bemarituzumab + chemo boosts survival in gastric cancer with FGFR2b. Read more here.

SHANGHAI, June 30, 2025 /PRNewswire/ -- On June 30th, Beijing time, Unisound, a pioneer in the industrialization of AI technologies in China and a portfolio company of Qiming Venture Partners, has successfully debuted on the Hong Kong Stock Exchange. Unisound (SEHK:9678) was issued at HK$205.00 per share, with a market capitalization of HK$14.545 billion.

U.S. stocks were slightly higher, with the Dow Jones index gaining around 0.1% on Wednesday. Shares of Guidewire Software, Inc. GWRE rose sharply during Wednes...

Zai Lab (ZLAB) announced positive Phase 1 data for ZL-1310 at the 2025 ASCO Annual Meeting. The study demonstrated a 67% objective response rate in seco

Zai Lab Limited (NASDAQ:ZLAB) and NovoCure Limited (NASDAQ:NVCR) revealed landmark results from the Phase 3 PANOVA-3 trial at the 2025 ASCO Annual Meeting, marking the first therapy to show statistically...

The Phase 3 PANOVA-3 trial shows TTFields therapy significantly improves overall survival in pancreatic cancer. TTFields therapy demonstrated a 2-month

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conf

Zai Lab Limited (NASDAQ:ZLAB; HKEX: 9688) will participate in multiple investor conferences in June 2025. The events include the Jefferies Global Health

Zai Lab Limited gains momentum with FDA Fast Track nod and solid earnings, signaling growth potential. Click here to find out why ZLAB stock is a Buy.

Zai Lab's ZL-1310 receives FDA fast-track & orphan drug status for small cell lung cancer. Read more here.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZL-1310, the Compa

Zai Lab Limited (NASDAQ:ZLAB) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsChristine Chiou - Senior Vice President, Investor...

We recently published a list of 11 Best Breakout Stocks to Buy According to Analysts.